Radiopharmaceuticals in Nuclear Medicine Market Size, Share, Growth, and Industry Analysis, By Type (Diagnostic Nuclear Medicine,Therapeutic Nuclear Medicine), By Application (Hospitals,Specialty Clinics,Diagnostic Centers), Regional Insights and Forecast to 2035

Radiopharmaceuticals in Nuclear Medicine Market Overview

The global Radiopharmaceuticals in Nuclear Medicine Market is forecast to expand from USD 6771.03 million in 2026 to USD 7167.82 million in 2027, and is expected to reach USD 10681.99 million by 2035, growing at a CAGR of 5.86% over the forecast period.

The Radiopharmaceuticals in Nuclear Medicine Market Market includes radionuclides, radiotracers, and theranostic agents used in imaging and therapy. Over 50 million nuclear medicine procedures are performed annually worldwide, with roughly 90 % for diagnostic purposes. Technetium-99m (Tc-99m) accounts for ~80 % of diagnostic scans globally and ~85 % of nuclear medicine imaging. More than 10,000 hospitals use radioisotopes in medical imaging, and about 1 in 50 persons in developed countries undergoes a nuclear medicine diagnostic each year. Radioisotope therapy procedures are about one-tenth of diagnostic volumes.

In the United States, nuclear medicine procedures exceed 20 million annually, with ~80 % being diagnostic scans. The U.S. performs more than double the European volume: Europe has ~10 million nuclear medicine procedures annually, of which ~2 million are therapeutic. About 5,000 U.S. facilities are equipped for radiopharmaceutical use. In one study, the U.S. nuclear medicine market was valued at ~USD 5.1 billion in 2023, with ~60.7 % of diagnostic demand via SPECT. Nearly 48 % of world radiopharmaceutical revenues are attributed to U.S. operations. The U.S. cancer incidence of ~1.96 million new cancer cases in 2023 drives demand for diagnostic and therapeutic radiopharmaceuticals.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 90 % of nuclear medicine procedures globally are diagnostic, fueling radiopharmaceutical demand.
• Major Market Restraint: 60 % of Mo-99 supply is dependent on five aging reactors, constraining throughput.
• Emerging Trends: 25 % of new radiopharmaceutical pipelines in 2024 emphasize alpha-emitter therapy.
• Regional Leadership: North America holds ~43.95 % share of radiopharmaceutical market dynamics in 2024.
• Competitive Landscape: Top two firms account for ~20 % of global radiopharmaceutical supply.
• Market Segmentation: Diagnostic radiopharmaceuticals have ~73 % share within nuclear medicine applications.
• Recent Development: In 2025, a manufacturer announced scaling of Lu-177 production by 30 %.

Radiopharmaceuticals in Nuclear Medicine Market Latest Trends

In recent years, the Radiopharmaceuticals in Nuclear Medicine Market Market Trends emphasize growth in theranostics, radiotracer diversification, and local production of isotopes. Diagnostic radiopharmaceuticals continue to dominate: in 2023, the diagnostic segment held ~73 % share of nuclear medicine product usage. Advances in PET radiotracers using F-18, Ga-68, and novel tracers have increased PET’s share from ~20 % to ~25 % of diagnostic scans. The therapeutic segment sees rising adoption of Lu-177, Y-90, and alpha emitters; approximately 25 % of new pipeline projects in 2024 concentrate on targeted alpha therapies.

Radiopharmaceuticals in Nuclear Medicine Market Dynamics

DRIVER

"Rising prevalence of cancer and chronic disease"

The principal growth driver in Radiopharmaceuticals in Nuclear Medicine Market Analysis is the increase in incidence of cancer, cardiovascular disease, and neurological disorders. In 2023, ~1.96 million new cancer cases were recorded in the U.S. alone; globally, cancer incidence continues upward. Nuclear medicine plays a central role in oncology diagnostics, staging, and therapy; ~41.65 % of nuclear medicine oncology imaging usage is used in radiopharmaceutical workflows. The therapeutic radiopharmaceutical segment appeals by combining diagnostics with treatment (theranostics). ~90 % of nuclear medicine procedures are diagnostic, supporting radiopharmaceutical imaging demand. Aging populations and growing chronic disease burden support sustained demand for imaging and radionuclide therapy. Hospitals invest in PET/CT and SPECT systems: in the U.S., ~60.7 % of diagnostic nuclear medicine is via SPECT. The complementary growth in hybrid imaging drives demand for novel tracers and radiopharmaceutical agents, reinforcing foundational momentum in this market.

RESTRAINT

"Supply constraints and aging reactor dependency"

A major restraint in Radiopharmaceuticals in Nuclear Medicine Market Market Analysis is the limited and concentrated supply of key isotopes. About 60 % of the global supply of Mo-99 (molybdenum-99, precursor to Tc-99m) originates from just five aging reactors, exposing vulnerability to outages or maintenance. As a result, ~25 % of scheduled diagnostic procedures are delayed in some regions. Production delays, regulatory export constraints, and transport complexity restrict throughput. The dependency on reactor-based supply also increases cost risk: raw isotope cost volatility affects ~30 % of radiopharmaceutical manufacturers. Some smaller producers report ~12 % margin erosion due to supply constraints. These structural limitations impede scaling supply to meet diagnostic and therapeutic demand simultaneously.

OPPORTUNITY

"Expansion of theranostics and decentralized isotope production"

Radiopharmaceuticals in Nuclear Medicine Market Opportunities lie in growth of theranostics and local isotope manufacturing. Around 25 % of new radiopharmaceutical research in 2024 focused on alpha-emitter therapy combinations (e.g. Ac-225, Pb-212). Many companies are building cyclotron or generator infrastructure locally; in emerging markets, ~15 % more local radiopharmaceutical production capacity came online in 2024. Theranostic pairs (diagnostic + therapeutic agents) now appear in ~18 % of nuclear medicine clinical trials. MRI-PET hybrid imaging centers are integrating radiopharmaceutical use, with ~12 % of new centers built with internal radiochemistry labs. Governments in ~10 nations increased funding for domestic isotope production to reduce import reliance. These moves align with Radiopharmaceuticals in Nuclear Medicine Market Market Forecast projections and underscore opportunities in localization, innovation, and therapy integration.

CHALLENGE

"Regulatory complexity, short half-lives, and logistics"

A significant challenge in Radiopharmaceuticals in Nuclear Medicine Market Industry Analysis is managing regulatory approval, the short half-lives of many radionuclides, and cold-chain logistics. Many radiopharmaceuticals have half-lives measured in hours (e.g. F-18 ~110 min, Tc-99m ~6 hours), demanding precise manufacturing, transport, and scheduling. ~10 % of doses degrade or are wasted due to logistics delays. Regulatory approval for new tracers can require multi-year trials; ~45 % of startups face delays beyond 12 months. Strict packaging, licensing, and cross-border transport rules escalate overhead ~20 % for many producers. Infrastructure needs (hot cells, radiochemistry labs, shielded transport) demand large capital; ~30 % of prospective markets lack sufficient facility capacity. These challenges slow tracer adoption, inflate cost, and constrain scale, complicating Radiopharmaceuticals in Nuclear Medicine Market Strategy planning.

Radiopharmaceuticals in Nuclear Medicine Market Segmentation

The Radiopharmaceuticals in Nuclear Medicine Market Market Analysis divides by type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine) and application (Hospitals, Specialty Clinics, Diagnostic Centers). The diagnostic segment dominates given routine imaging, while the therapeutic segment is rapidly expanding. Hospitals remain the primary application channel, but specialty clinics and diagnostic centers are increasing their share. This segmentation is central to Radiopharmaceuticals in Nuclear Medicine Market Insights, Market Share, and Market Growth.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Diagnostic Nuclear Medicine: Diagnostic radiopharmaceuticals comprise approximately 73 % of total market activity. Tc-99m remains the leading isotope, used in 85 % of global diagnostic scans. PET tracers such as F-18 and Ga-68 represent 25 % of diagnostic applications. The number of installed PET/CT scanners rose 18 % between 2022 and 2024. In cardiology, ~18 % of diagnostic nuclear medicine scans employ SPECT-based radiopharmaceuticals, while oncology and neurology account for 42 % and 12 %, respectively. Diagnostic imaging using radiopharmaceuticals supports over 50 million scans annually across more than 10,000 hospitals worldwide.

Therapeutic Nuclear Medicine: Therapeutic radiopharmaceuticals account for approximately 27 % of total use, with rapid growth in oncology. Lu-177 and Y-90 isotopes represent 60 % of the therapeutic segment, while alpha-emitters like Ac-225 and Pb-212 cover 10 % and rising. Around 2 million therapeutic procedures are performed yearly. In 2024, 25 % of radiopharma R&D was devoted to targeted alpha therapy. Radioligand therapy (RLT) and peptide receptor radionuclide therapy (PRRT) are used in 12 % of oncology treatment centers. Therapeutic radiopharmaceutical demand rose 14 % globally between 2022 and 2024, underscoring clinical integration momentum.

BY APPLICATION

Hospitals: Hospitals handle around 60 % of all radiopharmaceutical procedures. In 2024, approximately 5.8 million nuclear scans were performed within hospital systems globally. Roughly 30 % of large hospitals maintain on-site radiopharmacy labs for tracer preparation. In the U.S., hospitals conduct 60 % of SPECT imaging and 55 % of PET scans. European hospitals administer ~2 million therapeutic procedures annually. Hospitals remain central to both diagnostic and therapeutic applications, integrating radiopharmacy infrastructure, patient management, and quality control.

Specialty Clinics: Specialty clinics represent an expanding segment, accounting for about 25 % of radiopharmaceutical utilization. Nonhospital nuclear medicine procedures increased 2.5 % between 2022 and 2024. Oncology and neurology centers use radiopharmaceutical therapy in 41 % of advanced treatment cases. Outpatient centers are key early adopters of novel tracers. Roughly 20–25 % of radiopharmaceutical distribution in developed countries flows through specialty clinics. The flexibility and reduced capital requirements of clinics make them ideal for decentralized radiopharmaceutical service delivery.

Diagnostic Centers: Diagnostic imaging centers contribute 10–15 % of radiopharmaceutical demand. Standalone facilities focus on PET and SPECT imaging services. PET/CT scanners in diagnostic centers increased by 12 % in 2024. Contracted isotope supply chains serve 80 % of these centers. Diagnostic centers’ shorter approval cycles accelerate tracer adoption. In developing countries, diagnostic centers’ share of radiopharmaceutical consumption has grown 5 % annually since 2021. Their agility strengthens radiopharmaceutical market penetration and supports the Radiopharmaceuticals in Nuclear Medicine Market Market Growth narrative.

Radiopharmaceuticals in Nuclear Medicine Market Regional Outlook

The Radiopharmaceuticals in Nuclear Medicine Market Market Outlook displays strong regional variance: North America: dominant share and advanced infrastructure Europe: high adoption in diagnostics and therapy Asia-Pacific: fastest growth and emerging local production Middle East & Africa: nascent but increasing investments

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America commands a dominant position in the Radiopharmaceuticals in Nuclear Medicine Market Share. In 2024, North America accounted for ~43.95 % of radiopharmaceutical market share. The U.S. alone performed over 20 million nuclear medicine procedures annually, with ~5.85 billion USD market value in 2023 estimates. Hospitals in the U.S. perform ~60.7 % of diagnostic imaging via SPECT. Over 5,000 U.S. facilities hold radiopharmacy capacity. Legacy infrastructure supports high uptake of therapeutic radiopharmaceuticals; many centers offer PRRT and radioisotope therapies. In 2023, hospital-based procedures declined ~10.7 %, but outpatient and specialty settings grew ~2.5 %. North America remains central to pipeline launches, radiopharma investment, and regulatory innovation in Radiopharmaceuticals in Nuclear Medicine Market Research Report.

EUROPE

Europe holds significant share in radiopharmaceutical deployment, with ~10 million nuclear medicine procedures annually, ~2 million therapeutic. Diagnostic scans dominate; about 85 % of diagnostic imaging uses Tc-99m across many European nations. European investment in cyclotron, generator systems, and radiopharmacy infrastructure rose ~12 % in 2023–2024. Many EU countries now support reimbursement for diagnostic and therapeutic radiopharmaceuticals. Germany, France, UK, and Scandinavian nations lead in adoption of PET tracers and PRRT. About 30 % of newly installed radiopharmacy facilities in EU are optimized for Lu-177 handling. Europe is a key region in Radiopharmaceuticals in Nuclear Medicine Market Outlook, combining high standards and adoption.

ASIA-PACIFIC

Asia-Pacific is the fastest-growing region in Radiopharmaceuticals in Nuclear Medicine Market Analysis. In 2024, this region contributed ~15–20 % of global radiopharmaceutical volume but is expanding. Several nations (China, India, South Korea) initiated local isotope production capacity in recent years; local cyclotron facilities increased ~15 % in Asia in 2024. Diagnostic imaging usage per million people remains lower versus developed markets, indicating significant growth potential. Many oncology centers in Asia now adopt PET tracers; in India, ~30 % of new cancer centers include radiopharmacy labs. The region also sees regulatory modernization: ~10 national regulatory agencies streamlined tracer approval in 2023–2024. Asia-Pacific thus presents strong upside in Radiopharmaceuticals in Nuclear Medicine Market Growth and Market Forecast.

MIDDLE EAST & AFRICA

Middle East & Africa represent an emerging region in radiopharmaceutical adoption. In many nations, access to reliable isotope supply is limited. A few Gulf nations have invested in local radiopharmacy and cyclotron services in 2023–2024. Some hospitals in UAE and Saudi Arabia now administer PRRT therapies. However, public health expenditures and regulatory capacity limit scale; only ~5–8 % of global radiopharmaceutical volume is currently consumed. Radiopharmaceutical trials are few: ~2–3 % of global tracer trials include Middle East sites. As healthcare infrastructure improves and oncology demand rises, MEA may become a rising region in the Radiopharmaceuticals in Nuclear Medicine Market Market Opportunities.

List of Top Radiopharmaceuticals in Nuclear Medicine Companies

• IBA Group
• Institute Of Radioelement (IRE)
• Board of Radiation And Isotope Technology (BRIT)
• Eczacibasi-Monrol
• NTP Radioisotopes (Pty), Ltd.
• Australian Nuclear Association And Technology Organization (ANSTO)
• Rotem Industries, Ltd.
• Bracco Imaging S.P.A.
• Institute of Atomic Energy Polatom Radioisotope Centre
• Lantheus Medical Imaging, Inc.
• Urenco Limited
• Isotec, Inc. (Sigma-Aldrich)
• Cardinal Health, Inc.
• Cambridge Isotope Laboratories, Inc.
• Fujifilm Holdings Corporation
• Taiyo Nippon Sanso Corporation
• Nordion, Inc.
• GE Healthcare (Subsidiary Of General Electric Company)
• Institute of Isotopes Co., Ltd.
• Siemens Healthcare (Subsidiary Of Siemens AG)
• Covidien, Plc

Top two companies with the highest market share:

• GE Healthcare is widely recognized as a leading supplier of radiopharmaceuticals and imaging systems, often capturing top market share in diagnostics and tracer supply.
• Nordion, Inc. holds significant share in global radioisotope supply, especially in generator and tracer distribution chains.

Investment Analysis and Opportunities

Investment in the Radiopharmaceuticals in Nuclear Medicine Market Market is accelerating around isotope production, tracer pipeline expansion, and infrastructure development. In 2024, nearly 60 % of Mo-99 supply depended on a handful of reactors, prompting funding into reactor refurbishment and alternative production (cyclotron, generator). Several companies announced ~30 % increases in Lu-177 production capacity. Government and institutional grants for domestic isotope capability grew ~15 % in emerging markets. Clinical trial investment in new tracers rose ~25 % from 2022–2024. Infrastructure investment in radiopharmacy labs expanded ~12 % annually in Asia and Europe.

New Product Development

New product development in Radiopharmaceuticals in Nuclear Medicine Market Industry Report is focusing on novel tracers, improved targeting, and modular production. In 2024, ~25 % of new pipeline projects emphasized alpha-emitting radiopharmaceuticals. Next-generation F-18 tracers targeting neurological and cardiac receptors gained ~15 % share in tracer R&D. Novel bifunctional chelators for Lu-177 binding were developed in ~12 % of research programs. Modular, compact isotope generators for in-hospital production appeared in ~10 % of new manufacturing designs. Radiotracers with dual tracer/therapeutic capability (theranostics) represent ~18 % of new entries.

Five Recent Developments

• In 2024, a major radiopharma firm expanded Lu-177 production capacity by ~30 % to meet rising PRRT demand.
• In 2025, GE Healthcare announced a new F-18 tracer targeting Alzheimer’s pathology, advancing in ~15 % of clinical trial sites.
• In 2023, IRE upgraded Tc-99m generator output by 20 % to supply high-demand regions.
• In 2024, Nordion invested in a cyclotron facility in Asia to localize radionuclide supply and reduce import delays.
• In 2025, Eczacibasi-Monrol launched a novel Y-90 microsphere kit adopted by ~10 % of treating centers in Turkey.

Report Coverage

The Radiopharmaceuticals in Nuclear Medicine Market Market Report encompasses segmentation, regional analysis, competitive landscape, innovation pipelines, and investment insight. It covers type segmentation (Diagnostic Nuclear Medicine ~ 73 % share, Therapeutic ~ 27 %) and application segmentation (Hospitals, Specialty Clinics, Diagnostic Centers). Regional coverage includes North America (~43.95 % share), Europe, Asia-Pacific, and Middle East & Africa. Leading companies (GE Healthcare, Nordion) are profiled with market share, strategy, and product development. The report examines Market Trends (theranostics, decentralization), Market Dynamics (drivers, restraints, opportunities, challenges), and Market Forecast scenarios tailored for B2B stakeholders.

Radiopharmaceuticals in Nuclear Medicine Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 6771.03 Million in 2026
Market Size Value By	USD 10681.99 Million by 2035
Growth Rate	CAGR of 5.86% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Diagnostic Nuclear Medicine Therapeutic Nuclear Medicine By Application : Hospitals Specialty Clinics Diagnostic Centers
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample